Sat, Aug 23, 2014, 2:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • inetquirk inetquirk Dec 1, 2012 1:07 PM Flag

    Exceptional review

    Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an Outperform rating on Sunesis shares and raised his price target to $10 a share.

    RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

    This review establishes an opinion of: MARKET OUTPERFORM price target $20

    Investors will probably agree with this review using their due diligence/fact checking.

    Respectfully,
    Inetquirk

 
SNSS
6.92+0.18(+2.67%)Aug 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.